On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) CEO Outlines Next Steps for Promising New Technologies

  • Company is targeting $3.8 trillion preventative medicine industry
  • Sol-gel delivery system administers CBD-based medicines directly to the brain via nasal passages
  • Company R&D includes anti-diabetes and obesity gene therapy and powerful non-addictive painkiller

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) expects to make promising progress in the research and development of a number of exciting products in 2018, according to the company’s chairman, CEO and President Stephen Van Deventer in an audio interview (http://cnw.fm/7CrAF). He explained that, while pharmaceutical and nutraceutical companies are well-established, there is a relatively untapped $3.8 trillion a year industry in preventative medicine. Van Deventer said, “We coined the word ‘PreveCeutical’ for preventive medicine, which would be a combination of pharmaceuticals or nutraceuticals, but in the direction of preventive health.”

PreveCeutical is involved in researching and developing products aimed at preventing ailments before they start, thus improving people’s lifestyles. It is currently working on a number of promising projects, including Sol-gel, an innovative cannabidiol-based nose to brain delivery system being developed to give relief from epileptic seizures, pain, inflammation and other neurological conditions.

Van Deventer added, “As you’ve seen on YouTube (…), these people that have seizures, they take some cannabis oil and the seizures go away. Well, that’s not preventing; that’s actually stopping a seizure. So, we can now take these cannabinoids and infuse them to our Sol-gel, and people [can] take it once a week because it will sit in your mucosa and slowly time-release over one week. We can now get cannabinoids in your system and prevent these seizures from happening.”

The PreveCeutical CEO also spoke about other promising products in the company’s pipeline, including a powerful, non-addictive pain reliever and gene therapy to possibly prevent type 2 diabetes and obesity. The non-addictive pain reliever will be designed to “be stronger than morphine or any of the other opioids out there,” Van Deventer said. “However, it will have a few key elements: one, you can’t get high; two, you cannot create tolerance to it; and three, you cannot get addicted to it.”

He said that the company’s researchers, led by Chief Research Officer Harry Parekh, are keen for these life-changing technologies to be available to the mass market. While the cost of gene therapy can run into millions of dollars, Van Deventer said, “We hope to be able to deliver these gene therapies for thousands of dollars. You can have a few thousand dollars, rather than half a million or millions of dollars.”

Describing milestones for the near future, Van Deventer explained that PreveCeutical is planning some strategic acquisitions. “It would be nice to acquire some assets that are commercially viable now and start generating some revenues.”

The company is looking forward to releasing promising results on its research and development projects by the end of 2018.

For more information, visit the company’s website at www.PreveCeutical.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Contact us: 303.498.7722